

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 37/02, 39/00, C12Q 1/24</b>		A1	(11) International Publication Number: <b>WO 94/03202</b> (43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: <b>PCT/US93/07471</b>		(74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th Floor, One Market Plaza, San Francisco, CA 94105 (US).	
(22) International Filing Date: 10 August 1993 (10.08.93)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority data: 07/926,290	10 August 1992 (10.08.92)	US	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Box OTT, Bethesda, MD 20892 (US).			
(72) Inventors: LENARDO, Michael, J. ; 9117 Falls Chapel Way, Potomac, MD 20854-2453 (US). BOEHME, Stefen, A. ; 6514 Ivyhill Drive, McClean, VA 222101 (US). CRITCHFIELD, Jeffrey ; 1 Cloister Court, #106, Bethesda, MD 10814 (US).			

(54) Title: INTERLEUKIN-4 STIMULATED T LYMPHOCYTE CELL DEATH



(57) Abstract

This invention discloses a method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders and graft rejection. Specifically, it provides a means of killing a specific subpopulation of T lymphocytes while leaving the majority of other T lymphocytes in the population unaffected. The subpopulation of T lymphocytes are killed by repeatedly challenging the population with an antigen in conjunction with administration of interleukin-4.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

5

## INTERLEUKIN-4 STIMULATED T LYMPHOCYTE CELL DEATH

## BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates to the treatment and prevention of diseases that are primarily due to T cell immune responses. In particular, it relates to the suppression or elimination of certain autoimmune diseases, graft rejection, and allergic disorders by treatment with interleukin-4 (IL-4) 15 and the specific antigen involved, thus allowing the killing of only the subpopulation of T cells that recognizes this specific antigen. In this manner, IL-4 pretreatment sensitizes T cells to undergo programmed cell death following T cell receptor engagement.

20

Description of Related Art

25 Apoptosis is a form of programmed cell death that occurs in many biological systems (1-5). An apoptotic cell undergoes a specific program of events dependent upon active metabolism that contributes to its own self-destruction. Distinct morphological changes occur during this process such as membrane blobbing and cytoplasmic and nuclear condensation. These changes are accompanied by fragmentation of genomic DNA into pieces constituting one to several nucleosomes. In the 30 final stages, the cell disintegrates into apoptotic bodies that are specifically recognized and phagocytized by neighboring cells.

35

T lymphocytes are sensitive to apoptotic cell death induced by a variety of stimuli at multiple points in their lifespan. Experimental evidence strongly suggests that programmed cell death normally plays a large role in shaping and maintaining the T cell repertoire. Repertoire here is

defined by the number of distinct antigen receptor specificities contained in the entire pool of T lymphocytes in the organism. Each T lymphocyte bears surface receptors for antigen that are all of identical structure on that cell and therefore are said to represent a single antigen specificity. Since each T cell has a unique specificity, the total collection of antigen specificities in an organism is the sum of different individual T cells, thus the T cell repertoire. By eliminating or expanding the number of individual T cells, the responsiveness of an organism to a particular antigen can be either curtailed or enhanced, respectively. These changes have been documented to occur and are known as changes in the T cell repertoire. Alterations in the T cell repertoire occur naturally during T cell development such that only a small fraction of thymocytes (or immature T cells) survive the intrathymic development and selection events that allow emigration of developing T cells to the peripheral circulation (6,7). The majority of thymocytes appear to undergo apoptotic cell death in the thymus because they bear particular receptors. This "editing" of the T cell repertoire is thought to be the result of two processes: lack of positive selection, and negative selection or clonal deletion. The latter is fundamental to the establishment of self-tolerance as cells expressing potentially autoreactive receptors are actively eliminated. Fetal thymic organ culture (8), in vivo (9), and in vitro (10,11) experiments have shown that the double positive ( $CD4^+, CD8^+$ ) thymocytes appear to be more sensitive to apoptotic death induced by T cell receptor occupancy than more mature single positive cells. These double positive cells are also sensitive to programmed cell death induced by glucocorticoids (12).

Transformed T cells undergo activation-induced death from stimuli that are normally mitogenic for T cells (13-19). These include antigen, anti-TCR or CD3 mAb binding, the combination of phorbol ester and  $Ca^{2+}$  ionophore, and mAb modulation of alternative activation molecules Thy-1 and Ly-6. These cells are also susceptible to glucocorticoid-induced apoptosis. The processes of activation- and

glucocorticoid-induced programmed cell death are mutually antagonistic in transformed T cells (20-22).

Mature untransformed T cells have been shown to undergo apoptosis in response to various stimuli, such as IL-2 deprivation in the case of cells requiring IL-2 for viability (23), and modulation of the Fas antigen by the APO-1 mAb (24,25). Additionally, it has recently been demonstrated that IL-2 programs mature T lymphocytes to undergo apoptosis in response to antigen receptor stimulation both in vitro and in vivo (26). T cells must be under the influence of IL-2 prior to T cell receptor stimulation for apoptosis to occur, and the amount of cell death rises with increased amounts of IL-2. This process is selective, such that only stimulated T cells triggered by their specific antigen receptor and not by bystander cells undergo cell death. This apparent feedback pathway, termed propriocidal regulation, may represent a mechanism by which T cell responses are regulated (26).

The discovery that interleukin-4 (IL-4) predisposes T lymphocytes to programmed cell death, or apoptosis, allows for a novel method of therapeutic intervention in disease processes in humans and animals primarily caused by the action of IL-4-responsive T cells (27). In essence, this involves specifically inducing the death of a subpopulation of T lymphocytes that are capable of causing disease, while leaving the majority of T lymphocytes substantially unaffected. This method of intervention contrasts with, and is potentially far superior to, currently used therapeutic methods that cause a general suppression or death of T lymphocytes. Examples of widely-used general immunosuppressive agents are corticosteroids, such as prednisone, which are used to treat autoimmune diseases and allergic conditions, and cyclosporin A, which is used for treating graft rejection (28). These treatments suffer from the drawback of severely compromising immune defenses, by debilitating a large portion, if not the entire T cell repertoire. This leaves the patient vulnerable to infectious diseases. The two key elements of the present process are that: i) only the subset of T cells that reacts with antigens that cause the disease are affected by the

treatment; and ii) the T cells affected by the treatment are killed, i.e., they are permanently removed from the repertoire.

Several general principles underlie the present process. T cells recognize antigen in the form of short peptides that form noncovalent complexes with major histocompatibility complex (MHC) proteins on the surface of antigen-presenting cells found throughout the body (29). Antigens may also take the form of polysaccharides, organic molecules, or nucleic acids. Each T cell bears a unique antigen receptor called the T cell receptor (TCR) that is capable of recognizing a specific antigen-MHC complex. Through rearrangement of the gene segments containing the protein-coding segments of the TCR, a vast array, perhaps a virtually unlimited number of combinations, of different TCRs are generated (30). By a mechanism termed "allelic exclusion", each T cell bears a single unique TCR. The T cell repertoire is therefore a large number of T cells, each with a distinct TCR that recognizes a specific antigen-MHC complex. It is this vast array of T cells that allows immunological responses to the diversity of antigenic structures on invading micro-organisms, tumor cells, and allografts, thus preserving the integrity of the organism.

Most antigens are able to elicit a response in only a very tiny fraction of the T cell repertoire (31). For example, the initial response to protein antigens may involve as few as 1 in 1000 to 1 in 10,000 T lymphocytes (32). For this reason, diseases caused by T cell reactivity are mediated by only a small subset of the large repertoire of T cells (33). In particular, in those cases where, it has been directly measured, such as in multiple sclerosis, the fraction of the T cell repertoire which mediates disease is quite small (33). The important feature of the T cell subset that participates in disease is that it involves T cells which specifically recognize an antigen that provokes the disease. In allergic conditions, the antigen causes the release of inflammatory response molecules. For example, "helper" T cells secrete lymphokines such as IL-4 that cause B cells to

produce the inflammatory antibody IgE. In autoimmune diseases, the antigen may be derived from a specific organ in the body and, when recognized by a subset of T cells, stimulates the T cells to attack that organ. A similar effect 5 occurs during graft rejection. Antigenic proteins in the transplanted organ evoke a response in a subset of T cells that attacks the engrafted tissue. For unknown reasons, the fraction of T cells recognizing foreign or "allo" tissue is significantly higher than the number that will typically 10 recognize a protein antigen. Nonetheless, the number of responding T cells is still a distinct minority (1-10%) of the overall T cell repertoire (34).

In a typical T cell response to a specific antigen-MHC complex, stimulation of the TCR (35) results in a cascade 15 of gene activation events. These have been extensively characterized at the molecular level, and two such activation events are especially germane to the present invention i) production of growth lymphokines such as IL-4 and ii) expression of the cell surface proteins that constitute 20 high-affinity receptors for IL4. Resting T cells express small numbers of high affinity IL-4 receptors; this number increases following activation (36). IL-4 is a 15,000 dalton protein that causes T cells bearing the appropriate high affinity receptor to divide (37,38). The production of IL-4 25 followed by its interaction with its receptor causes an autocrine mechanism that drives the T cells into the cell cycle. This leads to an initial expansion of T cells that are specifically reactive with the antigen. At present, evidence indicates that in both the human and murine immune systems, a 30 subclass of T lymphocytes called CD4<sup>+</sup> T<sub>H</sub>2 cells may proliferate after antigen activation by producing and responding to IL-4 (39). This subset plays an important and perhaps unique role in stimulating B cells to produce immunoglobulin (Ig) (40). This is because IL-4 and other 35 lymphokines produced by T<sub>H</sub>2 cells, such as IL-5 and L-6, act as differentiation factors for B cells that are crucial for Ig production. Therefore, in autoimmune diseases in which Ig plays a pathogenetic role, the elimination of CD4<sup>+</sup> T<sub>H</sub>2

lymphocytes represents a highly effective way to halt disease. Our results and those of others (27,40-43) show that other classes of T cells including CD4<sup>+</sup> T<sub>H</sub>1 type lymphocytes that mediate delayed-type hypersensitivity as well as CD8<sup>+</sup> cells 5 that mediate cytotoxicity will also proliferate in response to IL-4 and are predisposed to TCR induced apoptosis. Therefore, IL-4 has a potentially broad role in T cell growth during immune responses. Thus, IL-4 could be broadly active in different classes of T cells to predispose them to apoptosis. 10 The present inventive discovery indicates that IL-4 also has the surprising effect of predisposing the expanded pool of either human or mouse T cells to apoptosis or programmed cell death if they are again stimulated or rechallenged through the TCR (27). In the present work described supra, the degree of 15 apoptosis achieved in T cells is correlated positively with both the level of IL-4 the cells experience during their initial expansion, the strength of the TCR stimulation upon rechallenge, and the timing of the rechallenge. In lymphokine-predisposed apoptosis, the effects wear off 2-3 20 days after lymphokine is no longer present, hence rechallenge must occur within that period (44). The process of activation and apoptosis eventually depletes the antigen-reactive subset of the T cell repertoire.

Apoptosis is a type of programmed cell death in 25 which the T cell nucleus shrinks, the genetic material (DNA) progressively degrades, and the cell collapses (1-5). Evidence suggests that cells cannot recover from apoptosis, and that it results in irreversible killing (1-5). T cells that do not undergo apoptosis but which have become activated 30 will carry out their "effector" functions by causing cytolysis, or by secreting lymphokines that cause B cell responses or other immune effects (45). These "effector" functions are the cause of tissue damage in autoimmune and allergic diseases or graft rejection. A powerful approach to 35 avoiding disease would therefore be to permanently eliminate by apoptosis only those T cells reactive with the disease-inciting antigens, while leaving the majority of the T cell repertoire intact. Apoptosis and T cell deletion caused by

antigenic stimulation have been demonstrated in model systems, but since a mechanism for this phenomenon was not previously known, it was not possible to use this in a therapeutically effective way (46-50).

5 By using IL-4 as an agent that predisposes T cells to death by TCR stimulation in appropriate cycle with immunization with the antigen(s) leading to autoimmune disease or graft rejection, the death of disease-causing T cells can be invoked. Specific methods are described for i) treatment of autoimmune or allergic diseases by identified protein antigen and IL-4, and ii) treatment of graft rejection by blood cell antigens and IL-4. Such methods, by logical extension, can be further developed for other diseases of man or animals that result from the effects of T cells activated by specific antigens. Because the vast majority of immune responses depend on T cell activation, it is predicted that this form of therapy could be applied to a wide variety of autoimmune and allergic conditions especially where antibody production is involved (51,52).

20 In several human autoimmune diseases, data have indicated that antigen-activated T cells play a key role in the production of disease. These include but are not limited to: 1) multiple sclerosis (53-58); 2) uveitis (59,60); 3) arthritis (61-63); 4) Type I (insulin-dependent) diabetes (64,65); 5) Hashimoto's and Grave's thyroiditis (66-68); and 25 6) autoimmune myocarditis (69). The ethical limits on human experimentation have made it very difficult to prove that T reactivity is the sole inciting agent of these diseases. Nonetheless, a large body of experimental work on animal 30 models -- murine experimental allergic encephalitis as a model for multiple sclerosis (70,71), BB diabetic rats for human diabetes (72,73), murine collagen-induced arthritis for rheumatoid arthritis (74,75), and S antigen disease in rats and guinea pigs for human autoimmune uveitis (76, 77), among 35 others -- suggests that T cells are the critical agent of these diseases. From recent work, the identity of disease-causing proteins or peptide antigens is emerging: i) multiple sclerosis: the peptide epitopes of myelin basic

protein (MBP) residues 84-102 and 143-168 (54,57,78,79); ii) autoimmune uveitis: the human S antigen, which has been recently molecularly cloned (59,80); iii) type II collagen in rheumatoid arthritis (81); and iv) thyroglobulin in thyroiditis (82). Similarly, a wide variety of proteins have been identified which stimulate the production of the allergic immunoglobulin IgE, which is the underlying immunological reaction for common allergies. IgE is produced by B lymphocytes in a process that requires lymphokines produced by antigen-activated T cells known as "T cell help". The class of CD4<sup>+</sup> "helper" T cells that stimulate B cells (T<sub>H</sub>2 cells) typically produce and respond to IL-4 (39,40).

The basic concept of the present therapeutic approach is very simple. Disease-causing T cells are first challenged by immunization to cause the activated T cells to express high affinity IL-4 receptors and, for T<sub>H</sub>2 cells, to begin producing and secreting IL-4. When the cells are expressing high levels of IL-4 receptor, additional human IL-4 is infused to very efficiently drive all the activated cells into the cell cycle. The cells under the influence of IL-4 are then caused to undergo apoptosis by re-immunization with antigenic peptide or protein. Further, if the antigen is capable of stimulating sufficient IL-4 production, it may not be necessary to administer exogenous IL-4. In either case, the timing of rechallenge is important -- it must occur within a short interval such as 2-3 days after the first stimulus when cells bear high levels of the IL-4 receptor and are responding to exogenous or endogenous IL-4.

The conceptual advance provided by the inventive discovery that underlies the present methods is that T cell immunity works as a balance between the production and destruction of antigen-specific T lymphocytes. Previously, investigators have focused on the use of lymphokine growth factors such as IL-4 to increase the proliferation and responsiveness of T lymphocytes (38,43,83-87). It is now proposed that the opposing T cell mechanisms be used therapeutically. The discovery that IL-4 predisposes T cells to death is contrary to the previously understood properties

of IL-4, and provides a radically new approach to the treatment of diseases caused by T cell reactivity. By providing physicians and medical researchers with the basis of the present inventive discovery, the processes of immune autoregulation leading to T cell destruction can be exploited in combatting disease.

It has been previously known for some time that prior activation and lymphokine production were capable of diminishing immune responsiveness both *in vivo* and *in vitro* (46-48). The mechanisms underlying these effects were not understood. Absent the knowledge that IL-4 predisposes T lymphocytes to antigen-dependent apoptosis, it was not possible to manipulate this phenomenon for medical or therapeutic purposes. It is now possible to rigorously study the kinetics and dose requirements of IL-4 in the predisposition phase, and antigen in the apoptosis phase, to routinely optimize the treatment cycle for a given disease following the guidance provided herein.

That this process depends on the discovery of a novel property of IL-4 is particularly auspicious. IL-4 has been thoroughly studied since its discovery in 1982 (85,86). It is well-understood genetically, its cDNA and gene have been molecularly cloned, and antibodies against the protein for immunodetection have been prepared (87,88). IL-4 is already available pharmaceutically in a form for use in humans and studies in human cancer victims have given insights into how IL-4 affects human physiology at different doses (89-92). All of these features significantly enhance the feasibility of its novel use to cause auto-destruction of disease-causing T lymphocytes for the treatment of a wide variety of diseases in humans and other mammals.

#### SUMMARY OF THE INVENTION

The present invention arose from the discovery that IL-4 programs mature T cells for antigen-driven death. The T cell death caused by IL-4 followed by antigen stimulation has hallmarks, such as DNA fragmentation, of "programmed cell death" or apoptosis. Thus, IL-4 acts as a death cytokine that

triggers the demise only of T cells that are specifically stimulated through their antigen receptor. This invention therefore allows the capability of altering the T cell repertoire much the same way that negative selection in the 5 thymus naturally eliminates T cells having certain antigen specificities. This novel use of a previously undiscovered property of IL-4 will allow the specific elimination of certain classes of antigen receptor-bearing T cells, forming the basis for new clinical applications of IL-4.

10 IL-4 is a lymphokine produced by T lymphocytes that was originally discovered to cause the growth of B lymphocytes (85). Later it was found that this molecule had pleiotropic activities on B cells such as increasing surface expression of MHC class II molecules, elevating immunoglobulin secretion and 15 class switching and inducing the presence of Fc $\epsilon$  receptors (93). Most importantly, IL-4 had powerful effects on both CD4 $^+$  and CD8 $^+$  T cells (37-43). IL-4 strongly enhanced the activity of cytolytic T cells which are involved in graft rejection (42). Also, IL-4 is a potent T cell growth factor 20 (37,38,43). Among helper T lymphocytes, IL-4 promotes the growth of T $H2$  cells that produce IL-4 in response to antigen stimulation and help B cells mount an antibody response (40).

25 A critical determinant of the choice between T lymphocyte proliferation or programmed cell death is the prior exposure of these cells to IL-4. Antigen receptor stimulation in T cells not exposed to IL-4 causes normal activation, leading to lymphokine production and growth. In contrast, T cells previously exposed to IL-4 undergo apoptosis after 30 antigen receptor stimulation. Therefore, antigen-activated T cells that are under the immediate influence of IL-4 will respond to rechallenge by antigen by undergoing apoptosis. The timing is significant because later antigenic stimulation can cause growth rather than apoptosis if the cells are no 35 longer under the influence of IL-4 if, for example, IL-4 is removed and the T cells are allowed to return to their resting state.

At least three uses for this novel property of IL-4 can be envisioned.

First, there is an emerging set of findings that show that infusion of peptides derived from antigens involved in autoimmune diseases leads to the lessening of severity of such diseases (cf. 94). A variety of studies of the 5 autoimmune disease experimental allergic encephalitis (EAE) shows that it is caused by the activation of T cells by immunization with myelin basic protein (MBP). Interestingly, infusion of peptides derived from the MBP sequence that stimulate the T cells that generate the disease are effective 10 at blocking the disease (71). The discovery disclosed herein provides an explanation for these seemingly paradoxical observations, which is that the T cells are activated and are potentially stimulated by IL-4 during peptide infusion, and then undergo apoptosis when they are restimulated by the MBP 15 antigen. Human diseases that have been associated with T cell activation by peptide antigens include multiple sclerosis and autoimmune uveitis (78,80). It is envisioned that these diseases, and, for example, systemic lupus erythematosus, 20 systemic vasculitis, polymyositis-dermatomyositis, systemic sclerosis (scleroderma), Sjogren's Syndrome, ankylosing spondylitis and related spondyloarthropathies, rheumatic fever, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, inorganic dust pneumoconioses, sarcoidosis, 25 autoimmune hemolytic anemia, immunological platelet disorders, cryopathies such as cryofibrinogenemia, autoimmune polyendo-crinopathies, and myasthenia gravis can be approached by therapy which can now be potentially modulated in a rationale way using IL-4 and the relevant peptide to cause apoptosis of the T cells responsible for the disease. Not all T cells have 30 a propensity to produce and respond to IL-4. However, the  $T_{H2}$  class of T lymphocytes which produce and respond to IL-4 are crucial as "helper" cells for immunological responses that involve the production of antibody. Many of the autoimmune diseases mentioned above have an antibody component that leads 35 directly to pathology (as in myasthenia gravis) or indirectly to pathology by immune complexes (as in systemic lupus) (51). Therefore, the elimination of  $T_{H2}$  "helper" cells may provide a significant amelioration or cure of these diseases. By

targeting a population of T cells that respond to IL-4 for apoptosis, this invention significantly extends a previous discovery that IL-2 predisposes T cells to apoptosis (26). The appropriate time of IL-4 infusion or a repetitive 5 immunization schedule could substantially augment the protective effect of the infused peptides.

Secondly, there is a significant body of literature 10 that suggests that pre-immunization of an animal or man prior to engraftment with a foreign tissue prolongs the survival time of the graft (cf. 95). One example of this phenomenon is the "donor-transfusion effect," in which transfusing a patient about to receive an organ transplant with blood from the organ donor decreases rejection of the transplant. Studies have 15 shown that CD8<sup>+</sup> cells will grow in response to IL-4 (42,43) thereby potentially rendering CD8<sup>+</sup> cells susceptible to IL-4-mediated apoptosis. This is the primary class of T cells involved in graft rejection. Based on the discovery of this 20 novel property of IL-4, CD8<sup>+</sup> T cells may be induced to undergo IL-4-mediated apoptosis; administering IL-4 during and immediately after the pre-immunization/transfusion phase, or repetitive immunization with MHC antigen at appropriately short intervals, could augment T cell death, leading to 25 greater tolerance of grafts.

Thirdly, a wide variety of atopic or allergic 30 disorders, commonly known as asthma or allergies, results from the effects of activating T cells, which causes both the release of harmful lymphokines and the production of IgE by B cells (96,97,98). Over the past few decades, clinicians have made primitive attempts to treat these diseases by a "desensitization" process consisting of repetitive exposure to 35 the same antigen that elicited the allergy (97). Despite the fact that very little is known about the mechanisms set in play by this procedure, in some cases such treatments were highly successful (97). An important scientific by-product of this work in clinical allergy is that considerable effort has gone into identifying proteins and other molecules that cause 40 allergic responses (98). This has led to the identification of protein sequences for antigens such as Amb a V and Amb t V,

which are ragweed allergens that cause hay fever, the protein sequence and characterization of antigenic peptides from allergen M that causes allergy to codfish (99), and the molecular cloning of the cDNA for antigen 5 of white-face 5 hornet venom, associated with allergy to hornet stings (100). Drugs that can cause allergy are typically small organic molecules that may become immunogenic by forming covalent complexes with host proteins. In addition, a large variety of allergens have been prepared as protein extracts to be 10 administered clinically to humans under the supervision of the Food and Drug Administration, and evaluated by a Panel on Review of Allergenic Extracts (97). With the molecular identification of these and other allergy-evoking antigens, it will be possible to immunize in cycle with IL-4 (See page 12 15 and Figure 3) to induce apoptosis of T cells involved in allergic disorders such as allergic rhinitis, bronchial asthma, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, Stevens-Johnson Syndrome, cutaneous 20 necrotizing venulitis, and bullous skin diseases.

Because a key component of the allergic response is the production IgE antibody that depends on "helper" T cells that respond to IL-4 (96), it is likely that IL-4 mediated apoptosis of T cells could have a significant effect on 25 allergic disease processes.

The key feature of each of these treatment protocols is that only the antigen-specific T cells, which comprise only a small component of the patient's T cell repertoire, would be eliminated. The treatment would leave the patient's immune 30 system largely intact. This is in contrast to present treatments that rely upon general immunosuppression that seriously incapacitates the host's immune function (see 101). Moreover, because this treatment causes death of the T 35 lymphocytes, it is superior to other recently discovered mechanisms which do not kill T cells but rather cause functional inactivation or anergy that is typically reversible (102-104). The experimental results described infra therefore

have broad clinical significance in applications to human immunological diseases.

Throughout the history of immunological approaches to human and animal diseases, beginning with the first 5 vaccination against smallpox carried out by Edward Jenner in 1798, the emphasis has been on stimulating a positive and protective antigen-specific immune response. In modern immunology, this is known to be due to activating lymphocytes. Hence, causing the activation and proliferation of 10 antigen-specific immune cells, especially T lymphocytes, forms the basis of most of the clinical applications of immunology. In particular, the recent advent of molecularly cloned cytokines, especially those with the ability to cause the proliferation of immune cells, has furthered the clinical 15 application of immunology. Such molecularly cloned cytokines can be readily prepared pharmacologically, and are powerful agents for stimulating the growth and division of lymphocytes. The conceptual and practical advance offered by the discovery disclosed herein is that cytokines such as IL-4, when given in 20 sufficient quantity, also cause negative regulatory effects such as T cell apoptosis. These regulatory effects represent built-in mechanisms to limit or suppress the immune response. Thus, the recognition that these mechanisms exist, and the 25 identification of a biologic, IL-4, that potently evokes antigen-specific T cell death, offers the opportunity to exploit the negative regulation of the immune response for the treatment of disease.

Accordingly, it is an object of the present invention to provide a method for treating or preventing 30 disease in a human or animal caused by antigen-activated T cells. This method induces the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing said disease to an extent greater than that of other T lymphocytes. Said disease can include an autoimmune disease, graft 35 rejection, or an allergic or atopic disorder, and said apoptosis can be achieved either by exploiting endogenous IL-4, or by administering this substance exogenously. When IL-4 is administered exogenously, apoptosis can be achieved by

a cycle comprised of challenging specific T cells via immunization with a substance selected from the group consisting of an antigen, a peptide, a protein, a polysaccharide, an organic molecule, and a nucleic acid, 5 followed by administering a high dose of IL-4 when said T cells are expressing high levels of IL-4 receptor, so as to cause said T cells to undergo apoptosis upon reimmunization with said substance. When endogenous IL-4 is employed to achieve apoptosis, said cycle comprises challenging said T 10 cells via immunization by repeated administration of said substance at intervals appropriate to cause apoptosis without the subsequent administration of a high dose of IL-4, relying instead on endogenous levels of IL-4.

Further scope of the applicability of the present 15 invention will become apparent from the detailed description and drawings provided below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and 20 modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 The above and other objects, features, and advantages of the present invention will be better understood from the following detailed descriptions taken in conjunction with the accompanying drawings, all of which are given by way of illustration only, and are not limitative of the present 30 invention, in which:

Figure 1. Photomicrographs of IL-4 treated A.E7 cells in the presence or absence of T cell receptor stimulation. IL-4 responsive A.E7 cells were cultured in medium alone or with platebound anti-CD3ε mAb (145-2C11) for 35 48 hours. For photomicroscopy, the medium was replaced with 0.4% trypan blue in phosphate buffered saline (PBS, 0.8 M potassium phosphate, 154 mM sodium chloride, and 2.9 mM sodium phosphate, pH 7.4). The trypan blue stain was removed and the

wells were gently washed three times with PBS only. Photomicrographs were made on a Zeiss Axiovert 405 M microscope using Hoffman modulation contrast optics.

Figure 2. A.E7 cells treated with IL-2 (14 U/ml) or 5 IL-4 (1000 U/ml) undergo apoptosis when cultured with anti-CD3 $\epsilon$  mAb (145-2C11). Analysis of DNA integrity by agarose gel electrophoresis of IL-2 stimulated (lanes 1 and 3), and IL-4 stimulated (lanes 2 and 4) A.E7 cells that were cultured in medium alone (lanes 1 and 2), or with platebound 10 anti-CD3 $\epsilon$  mAb (lanes 3 and 4).

Figure 3. Indicated is a chronological sequence of 15 treatments (above the line) and expected outcomes (below the line). Times for antigen inoculation and IL-4 infusion are discussed for the treatment of autoimmune diseases or red blood cells for preventing graft rejection. The hatched box indicates the earliest time frame for IL-4 treatment; the shaded box indicates optimal time for IL-4 treatment.

20

#### DETAILED DESCRIPTION OF THE INVENTION

The following detailed description of the invention is provided to aid those skilled in the art in practicing the same. Even so, the following detailed description should not be construed to unduly limit the present invention, as 25 modifications and variations in the embodiments herein discussed may be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

The disclosures of each of the references cited in 30 the present application are herein incorporated by reference in their entirety.

#### MATERIALS AND GENERAL METHODS

Materials. Female B10.A and BALB/c mice were 35 purchased from Charles River. Pigeon cytochrome  $c$ , and propidium iodide, as purchased from Sigma Chemical Co. (St. Louis, MO). Purified murine rIL-4 was kindly provided by Dr. W. Paul (National Institute of Allergy and Infectious

Diseases, NIH). The anti-murine IL-2 monoclonal antibody (mAb) S4B6.1 was generously provided by Dr. J. Zúñiga-Pflücker (National Institute of Allergy and Infectious Diseases, NIH). Anti-murine CD3ε mAb 145-2C11 (105) used in experiments was 5 immobilized by coating either 12- or 96- well culture plates (500  $\mu$ l or 100  $\mu$ l, respectively) (Costar, Cambridge MA), at a concentration of either 1  $\mu$ g/ml or 10  $\mu$ g/ml in phosphate-buffered saline (PBS) for 120 minutes or overnight at 37°C. The plates were washed three times with medium 10 (Click's or Eagle's Hank's amino acid, EHAA, and 10% FCS, 2 mM glutamine, 50  $\mu$ M  $\beta$ -mercaptoethanol, penicillin and streptomycin; Biofluids, Inc., Rockville, MD) before use. mAbs specific for MHC class II molecules (A<sup>k</sup>, 10.2.16; and E<sup>k</sup>, Y17), were a gift from Dr. R. Schwartz (National Institute of 15 Allergy and Infectious Diseases, NIH).

Cell culture. The murine nontransformed T cell clone A.E7 was carried as described previously (106). For experimentation, either resting cells (>2 weeks following 20 antigen stimulation) or antigen stimulated cells were used. Antigen stimulation consisted of culturing  $1 \times 10^6$  resting T cells with  $1 \times 10^7$  B10.A irradiated (3000R) splenocytes and 5  $\mu$ M pigeon cytochrome c in 2 mls total volume. After 48 hours, the antigen presenting cells (APCs) were removed by MHC class 25 II mAb mediated complement lysis (low-tox-M rabbit complement, Cedarlane Laboratories, Westbury, NY), and the cells were recovered by Lymphocyte M density centrifugation (Cedar Lane Laboratories) as previously described (41,104). The cells were then recultured for 48 hours in medium with 1% MLA 30 (gibbon ape leukemia cell supernatant containing 140 U/ml of IL-2 activity) or rIL-4 (10-1000 U/ml). T cells were then harvested and washed and assays were carried out in 96-well flat-bottomed plates in triplicate, with 200  $\mu$ l total volume for 48 hours.  $5 \times 10^4$  cells/well (with the exception of Table 35 I, Experiment 1 which was  $1 \times 10^5$  cells/well) were added with the designated lymphokine, either in the absence or presence of T cell receptor stimuli. The live cell number was then determined as described below.

5 T cell proliferation assays. A parallel culture of  $5 \times 10^4$  cells, without T cell receptor (TCR) stimulation, was pulsed by the addition of  $1 \mu\text{Ci}$  of [ $^3\text{H}$ ] thymidine ( $^3\text{H}$ -TdR) (6.7  $\mu\text{Ci}/\text{mmol}$ , New England Nuclear) for 16-24 hours. Cells were subsequently harvested onto glass filter paper, and the samples counted by liquid scintillation on an LKB betaplate counter. Data are expressed as the mean cpm of triplicates.

10 Cell viability. Viable cell number was determined by manual counting of trypan blue excluding cells using a hemocytometer by flow cytometry (FACS) with propidium iodide stained cells. For flow cytometry quantitation, cells were harvested by pipetting, washed once in phosphate buffered saline (PBS), and each sample was suspended in a constant 15 volume of PBS with propidium iodide (2  $\mu\text{g}/\text{ml}$ ). The fluorescence intensity of samples collected for a constant amount of time (100 sec.) was determined using a FACSCAN II analyzer with Lysis II software (Becton Dickenson, Mountain View, CA).

20 For this procedure, each sample is kept in a constant volume and the cells are collected for a constant amount of time, independent of the number of events. Only the live cell number, as gaged by forward scatter and propidium iodide exclusion, is quantitated. A comparison between 25 duplicate cultures analyzed for live cell number by trypan blue exclusion or flow cytometric analysis reveals that the relationship between these two quantitation methods is linear, evidenced by an R value  $>0.97$ .

30 Analysis of DNA fragmentation in agarose gels.  $1 \times 10^6$  cells were incubated in 12-well plates coated with anti-CD3 $\epsilon$  mAb for 48 hours, at which time the cells were harvested by gentle scraping and prepared by a modification of a previous procedure (8). Briefly, cells were washed once in PBS and incubated in 20  $\mu\text{l}$  of lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 500  $\mu\text{g}/\text{ml}$  proteinase K, and 0.5% sodium sarkosyl) for 1 hour at 50°C. RNase A (50  $\mu\text{g}/\text{ml}$ ) (Boehringer Mannheim) was added and the cells were incubated for an additional hour at 50°C. Dye buffer (10 mM EDTA, 1% (w/v) low

melting point agarose, 0.25% (w/v) bromphenol blue, and 40% (w/v) sucrose) was added, the samples were heated to 70°C for five minutes, quenched on ice, and electrophoresed in a 2% Nusieve agarose, 1% ultra-pure agarose gel with ethidium bromide.

5

Example I

IL-4 predisposes T cells to antigen-induced apoptosis.

10

We have previously shown that IL-2 participates in an apparent feedback pathway, termed propriocidal regulation, by predisposing T lymphocytes to antigen-induced apoptosis (26). We therefore determined if IL-4, another T cell growth factor, would induce this pathway. We first studied the nontransformed CD4<sup>+</sup> T<sub>H</sub>1 clone A.E7 that responds to pigeon cytochrome c in the context of an E<sup>k</sup> MHC class II molecule. This clone has been shown to upregulate its IL-4 receptor in response to antigenic stimulation and proliferate in response to IL-4 (41). As shown in Table 1, antigen stimulated A.E7 cells proliferate to IL-4 in a dose dependent manner, as indicated by tritiated thymidine (<sup>3</sup>H-TdR) incorporation (experiment 1). Moreover, there was a dramatic cell loss when the proliferating cells were subsequently placed onto anti-CD3ε-coated plates for 48 hours, as compared to the uncoated plate control. The reduction in cell number was minimal with no growth lymphokine added and increased roughly in proportion to the degree of proliferation achieved with increasing amounts of lymphokine. Cells treated with 1000 U/ml IL-4 showed an 84% decrease in cell number following TCR stimulation. The overall cell loss found with IL-4 was as great as that obtained with IL-2 stimulation (85% versus 87%, respectively).

20

We observed a similar phenomenon with the lymphokine-dependent T cell lines, CR.4R and CT.4S. We could not detect any T cell receptor surface expression in either cell line and anti-CD3ε stimulation had no effect on these cells (S.B. and M.L., unpublished results). Nonetheless, when TCR occupancy was mimicked by a combination of phorbol

25

myristic acetate (PMA) and ionomycin, extensive cell loss was observed after 48 hours (Table 1, experiment 2). Greater than 90% cell loss was observed for CT.4R cells exposed to either IL-2 or IL4, and 87% cell loss was seen for CT.4S cells 5 incubated with IL-4.

Several features of the cell loss in these experiments suggested that cell death was occurring. First, microscopic examination in all cases revealed cells appearing to undergo apoptosis. As shown in Figure 1, trypan blue 10 staining can detect non-viable cells (dark colored) in the cells stimulated with anti-CD3ε antibody more than in untreated samples. Second, the number of A.E7 cells following 1000 U/ml IL-4 and anti-CD3ε stimulation was less than the number of cells put into the wells implying cell loss in 15 addition to any potential block in proliferation (Table 1, experiment 1). Third, ladders of nucleosomal length DNA were obtained following IL-4 and anti-CD3ε treatment of A.E7 cells, indicating the occurrence of apoptosis. As shown in Figure 2, DNA fragmentation was observed in cells cultured with 20 platebound anti-CD3ε mAb (lanes 3 and 4), and was not observed in cells cultured with medium alone (lanes 1 and 2). We also observed cell death when IL-4 treated A.E7 cells were co-cultured with irradiated splenocytes and antigen (Table 1, experiment 3). Because IL-4 can stimulate the release of IL-2 25 under certain conditions (107), a mAb capable of binding IL-2 (S4B6.1) was included in the IL-4 stimulation. This did not inhibit subsequent T cell stimulation-induced apoptosis (Table 1, experiment 4), suggesting IL-4 treatment alone predisposes T cells to apoptosis.

Because these experiments were carried out in T cell clones that had been carried in vitro for a long period of time, we investigated whether IL-4 could predispose lymph node cells to apoptosis. Conditions for stimulating lymph node T (LNT) cells to produce lymphokines and proliferate in response 30 to either IL-2 or IL-4 have recently been determined (108). Treatment with TCR stimulation and IL-2 produces cultures exhibiting a predominantly T<sub>H</sub>1 phenotype producing and 35 responding to IL-2, whereas the inclusion of IL-4 leads to a

$T_{H2}$  phenotype of cells producing and responding to IL-4 (108). Freshly isolated lymph node cells were treated for 72 hours with either soluble anti-CD3 $\epsilon$  mAb or concavalin A, and IL-2 or IL-4. The LNT cells proliferated significantly in response to lymphokine in all samples (Table 2, CPM). There was large decrease in the number of live cells recovered following a 48-hour incubation on anti-CD3 $\epsilon$ -coated plates compared to the plastic control at all conditions tested (Table 2). These results show that IL-4 has the ability to predispose LNT cells to apoptosis. Furthermore, as was previously observed with IL-2 (26), IL-4 by itself can evoke the propriocidal pathway that leads to apoptosis following antigen receptor stimulation.

**Table 1. The effect of IL-4 and T cell receptor stimulation on T cell viability.**

<u>Expt.</u>	<u>Cells</u>	<u>Pretreatment<sup>1</sup></u>	<u>CPM</u>	<u>Cell Number (x10<sup>3</sup>/ml)</u>		<u>% Cell Loss</u>						
				<u>Control</u>	<u>Anti-CD3</u>							
1	A.E7	None	2,060	7.3 ± 0.7	5.4 ± 0.7	27						
	A.E7	14 U ml <sup>-1</sup> IL-2	173,845	37.3 ± 4.1	4.7 ± 0.4	87						
	A.E7	10 U ml <sup>-1</sup> IL-4	2,725	6.3 ± 0.3	4.7 ± 0.4	25						
	A.E7	100 U ml <sup>-1</sup> IL-4	17,833	10.1 ± 0.8	5.5 ± 0.8	45						
	A.E7	1000 U ml <sup>-1</sup> IL-4	89,159	18.6 ± 0.4	3.0 ± 0.4	84						
2	CT.4R	28 U ml <sup>-1</sup> IL-2	313,574	55.3 ± 5.4	2.9 ± 0.9	95						
3	CT.4S	1000 U ml <sup>-1</sup> IL-4	155,982	34.3 ± 4.6	3.6 ± 0.8	90						
4	A.E7	1000U ml <sup>-1</sup> IL-4 + S4B6.1	257,568	27.7 ± 1.8	3.6 ± 0.7	87						
<u>FACS Cell Number<sup>3</sup></u>												
<u>-Ag</u> <u>+Ag.</u>												
3	A.E7	1000U ml <sup>-1</sup> IL-4 + S4B6.1	257,568	22,703	5,348	76						
<u>Control</u> <u>Anti-CD3E</u>												
4	A.E7	14U ml <sup>-1</sup> IL-2	266,137	11.7 ± 1.6	2.6 ± 0.4	78						
5	A.E7	1000U ml <sup>-1</sup> IL-4	257,913	9.4 ± 1.7	1.9 ± 0.3	80						
<u>Control</u> <u>Anti-CD3E</u>												
6	A.E7	1000U ml <sup>-1</sup> IL-4	257,568	9.3 ± 1.3	2.0 ± 0.5	79						

<sup>1</sup>Indicates the treatment of A.E7 cells following 48 hour antigen stimulation. CT.4R and CT.4S cell lines did not undergo antigen stimulation but were pretreated as described. The concentration of lymphokine indicated was kept constant for each sample during the 48 hour pretreatment and the 48 hour duration of the experiment.

Table 1. (continued)

<sup>2</sup> these cells do not express TCR on the cell surface, so were cultured with PMA (10 ng/ml) and ionophore (2 $\mu$ M).

<sup>5</sup> <sup>3</sup> Indicates the live A.E7 cell number as determined by forward scatter profile, propidium iodide dye exclusion and surface staining with anti-mouse V $\alpha$ 11 mAb (Pharmingen) (see materials and Methods). Experimental conditions consisted of a 10-fold excess of B10. A irradiated spleen cells, 1 $\mu$ M pigeon cytochrome c(+ Ag) and 30  $\mu$ g of anti-mouse IL-2 mAb S4B6.1.

<sup>10</sup>

<sup>15</sup> Table 2. The effect of lymphokines and antigen receptor stimulation on lymph node cell viability.

<u>TCR Stim.</u>	<u>Lymphokine</u>	CPM	Cell Number		% Cell Loss
			<u>Control</u>	<u>Anti-CD3<math>\epsilon</math></u>	
Anti-CD3 $\epsilon$	IL-2	85,912	16,876 $\pm$ 3,775	7,917 $\pm$ 1,310	53
Con A	IL-2	54,835	28,226 $\pm$ 660	8,489 $\pm$ 2,804	70
Anti-CD3 $\epsilon$	IL-4	93,725	42,920 $\pm$ 3,409	4,628 $\pm$ 475	89
Con A	IL-4	81,562	36,930 $\pm$ 2,705	3,510 $\pm$ 887	91

<sup>20</sup> BALB/c lymph node cells were cultured at a concentration of  $1 \times 10^6$  cells/ml for 72 hours with soluble anti-CD3 $\epsilon$  (3 $\mu$ g/ml) or Concanavalin A (3  $\mu$ g/ml) in the presence of IL-2 (14 U/ml) or IL-4 (1000 U/ml). The cells ( $5 \times 10^4$  cells/well) were washed extensively and incubated with medium or anti-CD3-coated plates for an additional 48 hours in the presence of lymphokine. The cells were then harvested and the live cell number was determined by FACS analysis.

<sup>25</sup>

We previously proposed the term propriocidal regulation for the antigen receptor-stimulated apoptosis of mature T lymphocytes that were induced into the cell cycle by IL-2 (26). This mechanism would result in the elimination of any T lymphocyte that had a sufficient affinity for the inciting antigen. Our previous results suggest that in order for the T lymphocyte to undergo propriocidal cell death, it must be responding to IL-2 treatment, but not necessarily producing the lymphokine. We now extend these results to show that A.E7, a T<sub>H</sub>1 clone that can respond to, but not produce IL-4, will undergo apoptosis by TCR stimulation if actively cycling in response to IL-4 treatment. We have also shown that normal lymph node cells driven into cell cycle by antigen receptor stimulation and either IL-2 or IL-4 treatment, undergo cell death upon subsequent TCR stimulation. Cell cycling per se is not required, because we have found that certain blocking agents do not prevent TCR-mediated apoptosis (27). Nonetheless, agents that prevent progression beyond late G<sub>1</sub>, and not those that block proliferation in S phase, were found to be capable of inhibiting apoptosis (27). Thus, we favor the hypothesis that cell cycle progression beyond late G<sub>1</sub>, stimulated by growth lymphokines such as IL-2 or IL-4, is permissive for TCR-mediated death in T lymphocytes. It is likely that cell cycle progression beyond the late G<sub>1</sub> stage due to the transformed phenotype of T cell hybridomas and lymphomas accounts for their sensitivity to TCR-mediated apoptosis without lymphokine treatment (13-18). Our results suggest that an intrinsic property of the T lymphocyte response to a growth lymphokine such as IL-4 is the susceptibility to apoptosis upon further TCR stimulation. Moreover, this response portrays a mechanism by which an immune response to specific antigens may be naturally suppressed.

35 Example II

Method for IL-4/Peptide-Medicated Apoptosis of T Lymphocytes

As shown in Figure 3, immunization with a specific peptide or protein is carried out on day one. In the case of

multiple sclerosis, for example, there is evidence that either of two immunodominant peptides from myelin basic protein (MBP) are encephalitogenic in man; MBP 84-102 (the preferred peptide), or MBP 143-168 (78,79). Either or both of these peptides, coupled to tetanus toxoid, can be given in alum adjuvant intramuscularly (IM), at a dose between about 10 to about 1000  $\mu$ g. Early immunization experience using proteins or peptides has suggested that intramuscular administration is optimal (109-113). Newer data suggest that oral administration may also be effective (94). As with any medicinal substance, or biologic, tests on any peptides and proteins used for the immunization would need to be routinely carried out over a range of doses to determine: 1) the pharmacokinetic behavior of these substances; 2) their immunogenicity; and 3) safety and identification of any untoward effects. This would constitute a Phase I clinical trial (114). Thus, the particular proteins or peptides employed in this protocol (for example, in multiple sclerosis, MBP 84-102, or MBP 143-168; in uveitis, the S Antigen; or in rheumatoid arthritis, type II collagen) would require individual routine optimization. Similar intervention could be used with preparations of allergy-inducing proteins. These could be derived from a variety of allergen protein extracts that are now used clinically, or could be generated by recombinant DNA technology for those such as hornet venom antigen 5, for which cloned DNA is available (100). Ample evidence from the development of vaccines suggests that either synthetic peptides or recombinant DNA-derived proteins are effective in eliciting an immune response in humans (109-112). These studies also provide guidance as to the range of doses effective for immunization.

Proteins:

1) Hepatitis B surface antigen, produced as a recombinant protein in yeast. Adults 2.5 to 20  $\mu$ g; children 35 1.25 to 5  $\mu$ g intramuscularly (IM). 90-96% of vaccines showed an immune response, with the best response at 10-20  $\mu$ g (109). Further studies showed the efficacy of a 10  $\mu$ g dose, with better results when given IM rather than subcutaneously (110).

20  $\mu$ g doses in alum adjuvant given IM were found to be effective at preventing infection in clinical trials (111).

2) HIV gp 120, either natural or recombinant molecules. Doses in chimpanzees between 50-1000  $\mu$ g elicit T cell responses (115).

Peptides:

1) Chorionic gonadotropin. Several studies have indicated successful immune responses against a human chorionic gonadotropin- $\beta$  subunit peptide (residues 109-145) coupled to cholera or tetanus toxoid and given in doses from 50-1000  $\mu$ g in alum adjuvant (112).

2) Malaria sporozoite antigen. Studies of a Plasmodium falciparum peptide (NANP)<sub>3</sub> coupled to tetanus toxoid showed an immune response to doses of 20-160  $\mu$ g of peptide conjugate given IM, with the best response at 160  $\mu$ g (113).

Immunization is then followed by a waiting period during which the antigen activates the subset of T cells bearing reactive TCRS, causing them to express IL-4 receptors and possibly IL-4. This process will only upregulate IL-4 receptors on cells that have been antigenically-stimulated (36). Based on studies of both human and mouse T cells in vitro, between about 12 to about 24 hours after antigen exposure are required to express significant increases in the numbers of IL-4 receptors, and as long as about 72 hours are required to express optimal numbers of lymphokine receptors on the majority of T cells (36). Thus, the waiting period can be as short as about 12 hours or as long as about 72 hours, becoming increasingly optimal toward the upper end of this range.

This is then followed by an infusion of high doses of IL-4. Though only very limited data exists on the clinical use of IL-4 (89-92), a great deal of information has been obtained from clinical studies using IL-2. The administration of high-doses of the related T cell growth lymphokine IL-2 to humans has been well-studied in cancer patients, and various doses have been evaluated (116-120). Data indicate that IL-2 should be given intravenously (I.V.) either as frequent bolus

doses or as a continuous infusion (116-118). Doses that have been previously established range between about 300 to about 3000 units/kg/hour continuous infusion, or from  $10^4$  to  $10^6$  units/kg I.V. bolus (117). Units are defined by standards 5 available from the Biological Response Modifiers Program at the National Institutes of Health, and are defined as the quantity of IL-2 or IL-4 that gave 50% maximal thymidine incorporation in the bioassay under standard conditions. Side effects of these doses included chills, fever, malaise, 10 headache, nausea and vomiting, weight gain due to fluid retention, diarrhea, rash, and pruritis, which can all be treated with acetaminophen or indomethacin; no serious morbidity or mortality was observed. Studies of IL-4 administration to humans used human recombinant IL-4 of 15 specific activity  $1.5 \times 10^7$  units/ug, given in doses of 10-20 ug/kg body weight, three times/day. (89-91, 120,121) The side effects with IL-4 were similar to those observed with IL-2 and included weight gain due to water retention and nausea. After IL-4 treatment, the patient can be immediately 20 reimmunized with an equivalent dose of antigen. For example, for multiple sclerosis, treatment can be carried out with about 10 to about 1000  $\mu$ g of peptide MBP 84-102 coupled to tetanus toxoid and given in alum adjuvant IM. It is likely 25 that the preferred dose would be near the upper end of this range since greater TCR stimulation produces a greater level of apoptosis (26,27). IL-4 treatment would have stimulated the T cells bearing IL-4 receptors -- predominantly the disease-causing T cells -- and these cells would then be re-stimulated through their TCR. These cells will then 30 undergo apoptosis. After an immunization period of about 12 to about 72 hours, the cycle would begin again with reinfusion of IL-4. As will be described below, increased efficacy would likely result from multiple cycles of therapy. The treatment endpoints would be: i) elimination of in vitro reactivity to 35 the antigen, which can be easily measured where possible by various mixed lymphocyte or proliferation assays using peripheral blood lymphocytes; ii) amelioration of clinical symptoms; or iii) toxicity. The treatment endpoints for

allergic diseases would be: i) improvement of clinical symptoms; ii) normalization of an allergic skin test; iii) reduction in serum IgE levels; and iv) where possible to measure, reduced T cell responses to the allergenic protein.

5 Several features of the present therapy require further explanation. First, it is expected that T cells besides those antigenically stimulated may express high affinity IL-4 receptors. However, this should not diminish the specificity of the therapy because only those cells whose  
10 TCRs are stimulated by rechallenge with antigen will undergo apoptosis, as described supra. The effectiveness of the therapy could be variable depending on the nature of the antigen and the exact protocol employed. Extensive *in vitro* studies indicate that between 50-80% of the antigen-specific  
15 IL-4 stimulated T cells will undergo apoptosis when rechallenged by TCR stimulation (supra, 27). Second, the reduction in number of antigen-specific T cells determines the overall effectiveness of the therapy. Therefore, repeated cycles can substantially increase efficacy even if the level  
20 of killing in each cycle is only 50-70% (Table 3). As shown in the mouse studies, supra, the level of antigen-reactive T cells will decrease below the number of such cells prior to the first immunization with repetitive immunization.  
Furthermore, the expected toxicity of this protocol at  
25 moderate doses of lymphokine should be minor, and previous studies of the therapeutic use of growth lymphokines such as IL-2 or IL-4 in humans indicates that all side effects dissipate promptly following discontinuation of lymphokine treatment (89-91,116,117). The most serious side effect,  
30 fluid retention, should be minimized by the intermittent nature of IL-4 treatment. The 2-3 day rest period between doses would allow for diuresis of the fluid built up during IL-4 administration. Finally, the repeated administration of antigen will cause production of some endogenous IL-4, which  
35 will predispose some cells to apoptosis. While it is extremely unlikely that endogenous levels can reach the very high levels of IL-4 that can be administered pharmacologically, it is possible that empirically-determined

decreases in the IL-4 dose could be achieved because of endogenous IL-4 effects. The level of killing is dependent on the total level of IL-4 to which the T cell is exposed, and this will reflect a combination of endogenous and exogenous 5 sources (supra, 26,27).

With certain antigens, the predisposition of cells to apoptosis may be sufficiently induced by the endogenous production of IL-4. In these cases, appropriate immunization with antigen, in the absence of exogenously administered IL-4, 10 could produce T cell apoptosis and a protective effect. Based on the studies of the timing of susceptibility to apoptosis disclosed supra, immunizations repeated at specific intervals would be crucial for effective therapy. To effect IL-4-mediated apoptosis, immunizations would have to be repeated at 15 about 24 to about 120 hour intervals, preferably at about 24 to about 72 hour intervals, and would have to be repeated multiple times using antigen doses at about the high end of the ranges discussed above. T cell reactivity or 20 cell-mediated immunity for the specific antigen could then be monitored by in vitro assays to determine that T cells had undergone apoptosis. Absent the knowledge provided by the discovery disclosed herein, previous attempts to decrease immune responsiveness by repetitive immunization have not been optimal. For example, donor transfusion protocols to 25 ameliorate graft rejection involved 3 transfusions given at 2 week intervals (122, 123). Allergy shots, i.e., desensitization therapy, are typically given initially at 4-7 day intervals, after which intervals are progressively increased in length to 2 to 4 weeks (97). Based on the 30 present novel understanding of T cell apoptosis, the most effective immunization protocol would involve repetitive administrations of antigen at about 24 to 72 hour intervals.

Table 3

Theoretical number of reactive cells after  
fractional killing using IL-4 and T cell  
receptor stimulation

5

<u>Cycle</u>	<u>Fractional Killing</u>	<u>Reactive Cells Remaining</u>
Start	None	100,000
1	70%	30,000
2	70%	9,000
3	70%	2,700
4	70%	810
5	70%	243
6	70%	73

10 Theoretical values are based on starting with 100,000 cells and a constant killing efficiency of 70%. A reduction of over 100-fold is seen in 4 cycles and over 1000-fold in 6 cycles. At a fractional killing of 50%, a reduction of nearly 100-fold would be seen in 6 cycles. A first order kinetics is represented here because the process of apoptosis involves a single lethal hit delivery as has been shown for apoptosis induced by antimetabolites (1-5).

15

Example III

20 Method for transplantation antigen/IL-4-mediated apoptosis.

25 In medical procedures in which tissue is transferred between individuals who are genetically non-identical at their relevant histocompatibility antigen loci, herein referred to as allografting, and the transplanted tissue referred to as an allograft, the major problem encountered is rejection of the donor allograft by the host. The term "host" refers to the individual who is the recipient of the allograft, and the term 30 "donor" refers to the individual from whom the allograft is derived. Studies of the process of graft rejection have shown that it is due to the antigen-specific activation of T

lymphocytes, especially those bearing CD8 surface molecules (124). More importantly, agents that block the ability of T cells to mount an immune response in humans effectively prevent or lessen graft rejection (125). Since CD8<sup>+</sup> T cells 5 have been shown to be susceptible to apoptosis by IL-4, supra, this phenomenon can be used as a specific means to eliminate the reactive T cells, thereby avoiding graft rejection.

Essentially the same protocol with respect to timing and IL-4 dose can be used for this therapy as was described 10 supra for the therapy of autoimmune diseases. The major difference between this therapy and that described above is the source of antigen. Major histocompatibility complex (MHC) antigens are cell surface proteins that are tremendously polymorphic among individuals. Each individual's cells bear a 15 genetically determined set, or haplotype, of such antigens which serve as an immunological "fingerprint" on each cell (126). This allows one's immune system, in particular those responses generated by T cells, to recognize one's own cells, and to attack only cells that do not bear the self 20 "fingerprint" (127). There are two classes of MHC -- class I antigens, found on all cells in the body; and class II antigens, found predominantly on monocytes, macrophages, B lymphocytes, dendritic cells, and activated T cells (126). It 25 is the class I MHC antigens that are recognized by CD8<sup>+</sup> T cells that are the predominant influence in allograft rejection (124,1127). Because of this complexity of MHC antigens, the simplest source is cells from the allograft donor. It has been empirically observed that transfusion of a 30 graft recipient with donor blood suppresses graft rejection, although the mechanism of this effect is unknown, and the clinical effectiveness in many cases is modest (123). These protocols provide evidence that three transfusions of 200 ml of whole blood or packed cell equivalent from the donor is easily tolerated by the recipient with minimal side effects 35 (122). There is evidence that the donor-transfusion in some cases elicited sensitizing antibody responses in the allograft host, and these patients were not given allografts (122). These studies possibly represent an empirical observation that

preexposure to donor antigen suppresses the T cell response, although this is controversial (124). The present method includes administration of blood as a source of MHC antigens in doses of about 50 to about 200 ml to patients in cycle with 5 IL-4, as indicated in Fig. 4. In the case of kidney transplants, the amount of blood could be determined by the fluid tolerance of end-stage renal disease patients. The blood can be given as either whole blood, packed cells, or washed packed cell transfusions (123). The success of 10 treatment can be assessed by: i) a decreased requirement for general immunosuppressive medications; ii) graft survival; and iii) adequate function of the allograft. For example, the function of a transplanted kidney can be established by determining serum levels of creatinine and blood urea nitrogen 15 (125). This can be followed by IL-4 infusion and rechallenge with blood cells as antigen as shown in Figure 3.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the 20 spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

LIST OF REFERENCES CITED

1. Kerr, J.F.R., and B.V. Harmon. 1991. Definition and incidence of apoptosis: an historical perspective. In Apoptosis: the molecular basis of cell death, L.D. Tomei and F.O. Cope, ed. Cold Spring Harbor Laboratory Press, Plainview, New York, p. 5.
- 5 2. Lockshin, R.A., and Z. Zakeri. 1991. Programmed cell death and apoptosis. In Apoptosis: the molecular basis of cell death, L.D. Tomei and F.O. Cope, ed., Cold Spring Harbor Press, Plainview, New York, p. 47.
- 10 3. Cohen, J.J., R.C. Duke, V.A. Fadok, and K.S. Sellins. 1992. Apoptosis and programmed cell death in immunity. Ann. Rev. Immunol. 10:267.
- 15 4. Duvall, E. and A. H. Wyllie. 1986. Death and the cell. Immunology Today 7:115.
- 20 5. Cotter, T. G., S. V. Lennon, J. G. Glynn, and S. J. Martin. 1990. Cell death via apoptosis and its relationship to growth. Development and differentiation of both tumor and normal cells. Anticancer Research 10:1153.
- 25 6. von Boehmer, H. 1988. The developmental biology of T lymphocytes. Ann. Rev. Immunol. 6:309.
- 30 7. Marrack, P., and J. Kappler, 1987. The T cell receptor. Science 238:1073.
8. Smith, C. A., G. T. Williams, R. Kingston, E. J. Jenkinson, and J. J. T. Owen. 1989. Nature 337:181.
- 35 9. Shi, Y., R. P. Bissonnette, N. Parfrey, M. Szalay, R. T. Kubo, and D. R. Green. 1991. In vivo administration of monoclonal antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes. J. Immunol. 146:3340.
- 40 10. McConkey, D. J., P. Hartzell, J. F. Amador-Perez, S. Orrenius, and M. Jondal. 1989. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. J. Immunol. 143:1801.
- 45 11. Nieto, M. A., A. Gonzalez, A. Lopez-Rivas, F. Diaz-Espada, and F. Gampon. 1990. IL-2 protects against anti-CD3-induced cell death in human medullary thymocytes. J. Immunol. 145:1364.
- 50 12. Wyllie, A. H. 1980. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555.

13. Ashwell, J. D., R. E. Cunningham, P. D. Noguchi, and D. Hernandez. 1987. cell growth cycle block of T cell hybridomas upon activation with antigen. J. Exp. Med. 165:173.

14. Mercep, M., J. A. Bluestone, P. D. Noguchi, and J. D. Ashwell. 1988. Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules. J. Immunol. 140:324.

15. Ucker, D. S., J. D. Ashwell, and G. Nickas. 1989, Activation-driven T cell death. 1. Requirements for de novo transcription and translation and association with genome fragmentation. J. Immunol. 143:3461.

16. Nickas, G. J. Meyers, L. D. Hebshi, J. D. Ashwell, D. P. Gold, B. Sydora, and D.S. licker. 1992. Susceptibility to cell death is a dominant phenotype: triggering of activation-driven T-cell death independent of the T-cell antigen receptor complex. Mol. Cell. Biol. 12:379.

17. Shi, Y., M. G. Szalay, L. Paskar, M. Boyer, B. Singh, and D. R. Green. 1990. Activation-induced cell death in T cell hybridoma is due to apoptosis. J. Immunol. 144:3326.

18. Odaka, C., H. Kizaki, and T. Tadakuma. 1990. T cell receptor-mediated DNA fragmentation and cell death in T cell hybridomas. J. Immunol. 144:2096.

19. Takahashi, S., H. T. Maecker and R. Levy. 1989. DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. Eur. J. Immunol. 19:1911.

20. Zacharchuk, C. M., M. Mercep, P. K. Chakraborti, S. S. Simons, Jr., and J. D. Ashwell. 1990. Programmed T lymphocyte death. Cell activation and steroid-induced pathways are mutually antagonistic. J. Immunol. 145:4037.

21. Iseki, R., M. Mukai, and M. Iwata. 1991. Regulation of T lymphocyte apoptosis. Signals for the antagonism between activation- and glucocorticoid-induced death. J. Immunol. 147:4286.

22. Iwata, M., S. Hanaoka, and K. Sato. 1991. Rescue of thymocytes and T cell hybridomas from glucocorticoid-induced apoptosis by simulation via the T cell receptor/CD3 complex: a possible in vitro model for positive selection of the T cell repertoire. Eur. J. Immunol. 21:643.

23. Duke, R. C. and J. J. Cohen. 1986. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Research 5:289.

24. Watanabe-Fukunaga, R., C.I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.

5 25. Trauth, B. C., C. Klas, A. M. J. Peters, S. Matzku, P. Moller, W. Falk, K-M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301.

10 26. Lenardo, M. J. 1991. Interleukin-2 programs mouse  $\alpha\beta$  T lymphocytes for apoptosis. Nature 353:858.

15 27. Boehme, S. and Lenardo, M.J. (1992) Antigen receptor-induced apoptosis of nontransformed, mature T lymphocytes (propriocidal regulation) but not glucocorticoid-induced apoptosis, requires a distinct stage of the cell cycle (manuscript submitted).

20 28. Katz, P. and A.S. Fauci, Immunosuppressives and immunoadjuvants, Immunological Diseases, M. Somter et al., eds. (Boston: Little, Brown and Company), pp. 675-698 (1989).

25 29. Weiss, A., T lymphocyte activation, Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press), pp. 359-384 (1989).

30 30. Hedrick, S.M., T lymphocyte receptors, Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press), pp. 291-358 (1989).

35 31. Fink, P.J., M.J. Blair, L.A. Matis and S.M. Hedrick, Molecular analysis of the influences of positive selection, tolerance induction, and antigen presentation on the T cell repertoire. J. Exp. Med., 172:139 (1990).

40 32. Tse, H.Y., R.H. Schwartz and W.E. Paul, Cell-cell interactions in the T cell proliferative response, J. Immunol., 125:491-500 (1980).

45 33. Oksenberg, J.R., S. Stuart, A.B. Begovich, R.B. Bell, H.A. Erlich, L. Steinman and C.C.A. Bernard, Limited heterogeneity of rearranged T-cell receptor  $\text{V}\alpha$ -transcripts in brains of multiple sclerosis patients, Nature 345:344 (1990).

50 34. Lindahl, K.F. and D.B. Wilson, Histocompatibility antigen-activated cytotoxic T lymphocytes, J. Exp. Med. 145:508-522 (1977).

35. Crabtree, J., Contingent genetic regulatory events in T lymphocyte activation, Science 243:355-361 (1989).

55 36. Foxwell, B.M., Woerly, G., and Ryffel, B. (1989). Identification of interleukin-4 receptor-associated

proteins and expression of high and low affinity binding on human lymphoid cells, Eur. J. Immunol. 19:1637-41.

5 37. Spits, H. et al. 1987. J. Immunol. 139:1142.

38. Hu-Li, J. et al. 1987. J. Exp. Med. 165:157.

10 39. Mosmann, T.R. and Coffman, R.L., 1987. Two types of mouse helper T cell clone, Immunology Today 89:223-227.

40. Bottomly, K. 1988. Immunology Today 9:268.

15 41. Mueller, D. L., L. Chiodetti, P. A. Bacon, and R. H. Schwartz. 1991. Clonal anergy blocks the response to IL-4, as well as the production of IL-2, in dual-producing T helper cell clones. J. Immunol. 146:4118.

20 42. Widmer, M.B. and Grabstein, K.H. 1987. Nature: 326:795.

43. Grabstein, K.H. et al. 1987. J. Immunol. 139:1148.

25 44. Boehme, S. and Lenardo, M.J., 1992. Manuscript in preparation.

45. 45. Paul, W.E., The immune system: an introduction. Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press) pp. 3-38 (1989).

30 46. Russell, J.H., White, C.L., Loh, D.Y. & Meleedy-Rey, P. Proc. Natl. Acad. Sci. 88, 2151-2155 (1991); and Kawabe, Y. & Ochi, A. Nature 349, 245-248 (1991).

35 47. Liu, Y. & Janeway, C.A. Jr. J. Exp. Med. 172, 1735-1739 (1990).

48. Webb, S., Morris, C. & Sprent, J. Cell 63, 1249-1256 (1990).

40 49. Jones, L.A., Chin, L.T., Longo, D.L. & Kruisbeek, A.M. Science 250, 1726-1729 (1990).

50 50. Rocha, B. & von Boehmer, H. Science 251, 1225-1228 (1991).

45 51. Marsh, D.G. and Norman, P.S., Antigens that cause atopic diseases, Immunological Diseases, Fourth Edit., M. Samter et al, Eds. Vol. II, pp. 981-1002.

50 52. Middleton, E. et al, Eds., Allergy: Principles and Practice, Third edition, (St. Louis: C.V. Mosby) (1988).

55 53. Johnson, D, D.A. Hafler, R.J. Fallis, M.B. Lees, R.O. Brady, R.H. Quarles and H.L. Weiner, Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis, J. Neuroimmunology 13:99-108 (1986).

5 54. Martin, R., M.D. Howell, D. Jaraquemada, M. Flerlage, J. Richert, S. Brostoff, E.O. Long, D.E. McFarlin and H.F. McFarland, A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis, J. Exp. Med., 173:19-24 (1991).

10 55. Pette, M., K. Fujita, D. Wilkinson, D.M. Altmann, J. Trowsdale, G. Giegerich, A. Hinkkanen, J.T. Eppelen, L. Kappos and H. Wekerle, Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. USA 87:7968-7972 (1990).

15 56. Jaraquemada, D., R. Martin, S. Rosen-Bronson, M. Flerlage, H.F. McFarland and E.O. Long, HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals, J. Immunol. 145:2880-2885 (1990).

20 57. Martin, R., D. Jaraquemada, M. Flerlage, J. Richert, J. Whitaker, E.O. Long, D.E. McFarlin and H.F. McFarland, Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals, J. Immunol. 145:540-548 (1990).

25 58. Brinkman, C.J.J., W.M. Nillesen, O.R. Hommes, K.J.B. Lamers, B.E. dePauw, and P. Delmotte, Cell-mediated immunity in multiple sclerosis as determined by sensitivity of different lymphocyte populations to various brain tissue antigens, Ann. Neurology 11:450-455 (1981).

30 59. Hirose, S., L.A. Donoso, T. Shinohara, A.G. Palestine, R.B. Nussenblatt and I. Gery, Lymphocyte responses to peptide M and retinal S antigen in uveitis patients, Jpn. J. Ophthalmol. 34:298-305 (1990).

35 60. de Smet, M.D., J.H. Yamamoto, M. Mochizuki, I. Gery, V.K. Singh, T. Shinohara, B. Wiggert, C.J. Chader and R.B. Nussenblatt, Cellular immune responses of patients with uveitis to retinal antigens and their fragments, Am. J. Ophthalmol. 110:135-142 (1990).

40 61. Hawrylko, E., A. Spertus, C.A. Mele, N. Oster and M. Friari, Increased interleukin-2 production in response to human Type I collagen stimulation in systemic sclerosis patients, Arthritis Rheum., 34:580-587 (1991).

45 62. Abdel-Nour, A.N., C.J. Elson and P.A. Dieppe, Proliferative responses of T-cell lines grown from joint fluids of patients with rheumatoid arthritis and other arthritides, Immunol. Lett. 12:329-33 (1986).

50

55

5           63. Paliard, X., S.G. West, J.A. Lafferty, J.R. Clements, J.W. Kappler, P. Marrack and B.L. Kotzin, Evidence for the effects of a superantigen in rheumatoid arthritis, Science 253:325-329 (1991).

10           64. Bottazzo, G.F., B.M. Dean, i.M. McNally, E.H. MacKay, P.G.F. Swift and D.R. Gamble, In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis, New Engl. J. Med. 313:353-360 (1985).

15           65. Lundkin, K.E., G. Gaudernack, E. Qvigstad, L.M. Sollid and E. Thorsby, T lymphocyte clones recognizing an HLA-DQw3.2-associated epitope involving residue 57 on the DQ beta chain, Human Immunol., 22:235:46 (1988).

20           66. Davies, T., A. Martin, E.S. Concepcion, P. Graves, L. Cohen and A. Ben-nun, Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease, New Eng. J. Med. 325:238-244 (1991).

25           67. Volpe, R., Immunoregulation in autoimmune thyroid disease, New Eng. J. Med. 316:44-46 (1987).

30           68. Londei, M., G.F. Bottazzo and M. Feldman, Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells, Science 228:85-89 (1985).

35           69. Dale, J.B. and E.H. Beachey, Sequence of myosin-crossreactive epitopes of streptococcal M. protein, J. Exp. Med., 164:1785-1790 (1986).

40           70. Sobel, R.A., V.K. Tuohy and M.B. Lees, Parental MHC molecule haplotype expression in (SJL/J x SWR)F<sub>1</sub> mice with acute experimental allergic encephalomyelitis induced with two different synthetic peptides of myelin proteolipid protein, J. Immunol. 146:543-549 (1991).

45           71. Wraith, D.C., D.E. Smilek, D.J. Mitchell, L. Steinman and H.O. McDevitt, Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy, Cell 59:247-255 (1989).

50           72. Woda, B.A., E.S. Handler, D.L. Greiner, C. Reynolds, J.P. Mordes and A.A. Rossini, T-lymphocyte requirement for diabetes in RT6-depleted diabetes-resistant BB rats, Diabetes 40:423-8 (1991).

55           73. Metroz-Dayer, M.D., A. Mouland, C. Budeau, D. Duhmel and P. Poussier, Adoptive transfer of diabetes in BB rats induced by CD4 T lymphocytes, Diabetes 39:928-32 (1990).

74. Seki, N., Y. Sudo, A. Yamane, S. Sugihara, Y. Takai, K. Ishihara, S. Ono, T. Hamaoka, H. Senoh and H. Fujiwara, Type II collagen-induced murine arthritis. II. Genetic control of arthritis induction is expressed on L3T4+ T

cells required for humoral as well as cell-mediated immune responses to type II collagen, Reg. Immunol., 2:203-212 (1989).

5 75. Chiocchia, G., M.C. Boissier, M.C. Ronziere, D. Herbage and C. Fournier, T cell regulation of collagen-induced arthritis in mice. I. Isolation of type II collagen-reactive T cell hybridomas with specific cytotoxic function, J. Immunol., 145:519-25 (1990).

10 76. Caspi, R.R., F.G. Rfoberge, C.G. Mcallister, M. El Saied, T. Kuwabara, I. Gery, E. Hanna and R.B. Nussenblatt, T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat, J. Immunol., 136:9928-933 (1986).

15 77. Merryman, C.F., L. Donoso, X.M. Zhang, E. Heber-Katz and D.S. Gregerson, Characterization of a new potent immunopathogenic epitope in S-antigen that elicits T cells expressing V $\beta$ 8 and V $\alpha$ 2-like genes, J. Immunol. 146:75-80 (1991).

20 78. Ota, K., M. Matsui, E.L. Milford, G.A. Mackin, H.L. Weiner and D.A. Halfer, T-cell recognition of an immune-dominant myelin basic protein epitope in multiple sclerosis, Nature 346:183-187 (1990).

25 79. Pette, M., K. Fujita, D. Wilkinson, D.M. Altmann, J. Trowsdale, G. Giegerich, A. Hinkkanen, J.T. Eppen, L. Kappas and H. Wekerle, Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors, Proc. Natl. Acad. Sci. USA 87:7968-72 (1990).

30 80. Shinohara, T. V.K. Singh, M. Tsuda, K. Yamaki, T. Abe and S. Suzuki, S-Antigen: from gene to autoimmune uveitis, Exptl. Eye Res. 50:751-757 (1990).

35 81. Klimink, P.S., R.B. Claque, D.M. Grennan, P.A. Dyer, I. Smeaton and R. Harris, Autoimmunity to native type II collagen - a distinct subset of rheumatoid arthritis, J. Rheum., 12:865-70 (1985).

40 82. Canonica, G.W., M.E. Cosulich, R. Croci, S. Ferrini, M. Bognasco, W. Dirienzo, D. Ferrini, A. Bargellesi and G. Giordano, TITLE, Clinical Immunol. Immunopathol. 32:132-41 (1984).

45 83. Kupper, T. et al. Autocrine growth of T cells independent of Interleukin-2: identification of interleukin-4 (IL4, BSF-1) as an autocrine growth factor for a cloned antigen-specific helper T cell, J. Immunol. 138: 4280-4287 (1987).

84. Varma, C. et a., Interleukin 7 and interleukin 4 stimulate human thymocyte growth through distinct mechanisms, Cytokine 2:55-59 (1990).

5 85. Howard, M. et al., Identification of a T cell-derived B cell growth factor distinct from interleukin 2, J. Exp. Med., 155, 914-923 (1982).

10 86. Street, N.E. and Mosmann, T.R., Biotherapy 2, 347-362 (1990).

15 87. Solari, R. et al., Purification and characterization of recombinant human interleukin 4, Biochemical J. 262, 897-908 (1989).

18. Chretien, I., et al., Development of polyclonal and monoclonal antibodies for immunoassay and neutralization of interleukin-4, J. Immunol. Methods 117, 67-81 (1989).

20 89. White, M.V. et al., Blood, 79, 1491-1495 (1992).

90. Rubin, J.T. and Loize, M.T., Surgery 111, 274-280 (1992).

25 91. Loize, M.T., T cell growth factors and the treatment of patients with cancer, Clin. Immunol. Immunopath., 62, 547-54 (1992).

92. Maher, D.W., Davis, I., Boyd, A.W. and Morstyn, G., Human interleukin-4: an immunomodulator with potential therapeutic applications, Prog. Growth Factor Res., 3,43-56 (1991).

30 93. Gillis, S. "T cell derived lymphokines" in Fundamental Immunology, 2nd Edition, Ed. W. Paul, New York: Raven Press, 1989, pp- 629-630.

35 94. Marx, J., Testing of autoimmune therapy begins, Science 252:27-28 (1991).

40 95. El-Malik et al., Transplantation, 38:213-216 (1984).

96. Toda, T., Regulation of reagin formation. Prog. Allergy, 19:122 (1975).

45 97. Grammer, L.C., Principles of immunologic management of allergic diseases due to extrinsic antigens, Allergic Diseases, Diagnosis and Management, Third Edit., R. Patterson, Ed., PP-358-373.

50 98. Marsh, D.G. and Norman, P.S., Antigens that caused atopic diseases, Immunological Diseases, 4th Ed., M. Somter et al., Eds. Vol. II, pp. 981-1002.

55 99. Elsayed, S., Titlestead, K., Apold, J. et al. A synthetic hexapeptide derived from allergen M imposing allergenic and antigenic reactivity. Scand. J. Immunol., 12:171 (1980).

100. Fang, K.S.Y., Vitale, M., Fehlner, P. and King, T.P., CDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5, Proc. Natl. Acad. Sci. USA, 85:895-899 (1988).

101. M. Wayne Flye, Principles of Organ Transplantation, (Philadelphia: W.B. Saunders) (1989).

102. Schwartz, R.H., A cell culture model for T lymphocyte clonal anergy, Science, 248:1349-1356 (1990).

103. Morahan, G., Allison, J. and Miller, J.F.A.P., Tolerance of Class I histocompatibility antigens expressed extrathymically, Nature, 339:622-624 (1989).

104. Beverly, B., Kong, S.M., Lenardo, M.J. and Schwartz, R.G., Reversal of in vitro T cell clonal energy by IL-2 stimulation, Int'l. Immunol., 4, 661-671 (1992).

105. Leo, Ob., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.

106. Hecht, T. T., D. L. Longo, and L. A. Matis. 1983. The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J. Immunol. 131:1049.

107. Tanaka, T., S.Z. Ben-Sasson, and W.E. Paul. 1991. IL-4 increases IL-2 production by T cells in response to accessory cell-independent stimuli. J. Immunol. 146:3831.

108. Seder, R., Paul, W., Davis, M., and de St. Groth, B.F., J. Exp. Med., in press.

109. Zajoc, B.A., D.J. West, W.J. McAleer and E.M. Scolnick, Overview of clinical studies with Hepatitis B vaccine made by recombinant DNA, J. Infect. 13:(Suppl A)39-45 (1986).

110. Yamamoto, S., T. Kuroki, K. Kurai and S. Iino, Comparison of results for phase I studies with recombinant and plasma-derived hepatitis B vaccines, and controlled study comparing intramuscular and subcutaneous injections of recombinant hepatitis B vaccine, J. Infect. 13:(Suppl A) 53-60 (1986).

111. Francis, D.P. et al., The prevention of Hepatitis B with vaccine, Ann. Int. Med. 97:362-366 (1982).

112. Steven, V.C. and W.R. Jones, Vaccines to prevent pregnancy, New Generation Vaccines, G.C. Woodrow and M.M. Levine, eds. (New York: Dekker) pp. 879-900 (1990).

113. Herrington et al., Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium Falciparum sporozoites, Nature, 328:257-259 (1987).

5 114. Owen, J.A. Jr., Managing and conducting Phase I and Phase II clinical trials, Drug Development, Second Ed., C.E. Hamner, ed. (Boca Raton: CRC Press) pp. 159-174 (1989).

10 115. Putney et al., Features of HIV envelope and development of a subunit vaccine, AIDS Vaccine Research and Clinical Trials, S. Putney and B. Bolognesi, eds. (New York: Dekker) pp. 3-62 (1990).

15 116. Loize, M.T., L.W. Frana, S.O. Sharrow, R.J. Robb and S.A. Rosenberg, In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134:157-166 (1985).

20 117. Loize, J.T., Y.L. Malory, S.E. Ettinghausen, A.A. Rayner, S.O. Sharrow, C.A.Y. Seipp, M.C. Custer and S.A. Rosenberg, In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135:2865-2875 (1985).

25 118. Donohue, J.H. and S.A. Rosenberg, The fate of interleukin-2 after in vivo administration, J. Immunol. 130:2203-2208 (1983).

30 119. Belldegrun, A., M.M. Muul and S-A Rosenberg, Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity, Cancer Research 48:206-214 (1988).

35 120. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Malory, i.M. Skibber, E. Shiloni, J.T. Vetto, C.A. Seipp, C. Simpson and C.M. Reichert, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, New Eng. J. Med. 313:1485-1492 (1985).

40 121. Wong, H. et al, J. Immunol., 148:2118 (1991).

45 122. Salvatierra, O. et al., Deliberate donor-specific blood transfusions prior to living-related renal transplantation, Ann. Surg. 192:543-551 (1980).

50 123. Opelz, G., M.R. Mickey and P.I. Terasaki, Blood transfusions and kidney transplants: remaining controversies, Transpl. Proc. 13:136-141 (1981).

55 124. Ruiz et al., Evidence that pre-transplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ autoimmune or morphologic manifestations of rejection, Transplantation 45:1-7 (1988); and

Auchincloss, H. and D.H. Sachs, Transplantation and graft rejection, Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press) pp. 889-922 (1989).

5 125. Cosimi, A.B., R.C. Burton, R.B. Colvin, G. Goldstein, J.T. Herrin and P.S. Russell, Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation, 32:535-539 (1981); and Simmons, R.L. et al, Transplantation, Principles of Surgery, Fifth Edit., S.I. Schwartz, G.T. Shires, and F.C. Spencer, Eds., pp. 387-458.

10 126. Robinson, M.A. and T.J. Kindt, Major histocompatibility antigens and genes, Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press) pp. 489-540 (1989).

15 127. Carbone, F.J. and M.J. Bevan, Major histocompatibility complex control of T cell recognition, Fundamental Immunology, Second Ed., W.E. Paul, ed. (New York: Raven Press) pp. 541-5701 (1989).

20

WHAT IS CLAIMED IS

- 5           1. A method for inhibiting a T cell immune response in a human or animal, the method comprising repetitive administration of an antigen associated with the immune response in conjunction with the administration of interleukin-4, thereby eliminating T cells associated with the immune response.
- 10
- 15           2. A method of claim 1 wherein the T cell immune response is associated with an autoimmune disease.
- 20           3. The method of claim 2 wherein the autoimmune disease is multiple sclerosis.
- 25           4. The method of claim 2 wherein the autoimmune disease is autoimmune uveitis.
- 30           5. The method of claim 1 wherein the antigen is administered at about 24 to about 72 hour intervals.
- 35           6. The method of claim 1 wherein the antigen is a peptide.
- 40           7. The method of claim 1 wherein the antigen is myelin basic protein.
- 45           8. The method of claim 6 wherein the peptide is administered at a dose between about 10 to about 1000 µg.
- 50           9. The method of claim 1 wherein the interleukin-4 is administered about 12 to about 72 hours after the antigen is administered.
- 55
- 60           10. The method of claim 1 wherein the interleukin-4 is administered parenterally

11. The method of claim 1 wherein the interleukin-4 is administered via continuous infusion for between about 48 and about 72 hours.

5 12. A method for eliminating a preselected sub-population of T cells in a sample comprising antigen presenting cells, the method comprising contacting the sample with an antigen recognized by the T cells and interleukin-4.


10 13. A method of claim 12, wherein the antigen is associated with autoimmune disease.

14. The method of claim 13, wherein the autoimmune disease is multiple sclerosis.


15

20


*FIG. 1A.*



*FIG. 1B.*



4 3 2 1



*FIG. 2.*

2/2




FIG. 3.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 93/07471

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 5 A61K37/02 A61K39/00 C12Q1/24

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NATURE. vol. 353, no. 6347, 31 October 1991, LONDON GB pages 858 - 861 M.J. LENARDO 'INTERLEUKIN-2 PROGRAMS MOUSE ALPHA BETA T LYMPHOCYTES FOR APOPTOSIS.' cited in the application see the whole document</p> <p>-----</p> <p>EUROPEAN JOURNAL OF IMMUNOLOGY vol. 23, no. 7, July 1993, WEINHEIM, DE pages 1552 - 1560 S.A. BOEHME ET AL. 'PROPRIOCIDAL APOPTOSIS OF MATURE T LYMPHOCYTES OCCURS AT S PHASE OF THE CELL CYCLE.' see the whole document</p> <p>-----</p>	1-14
P, X		1, 12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

\*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*'&' document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
26 November 1993	06-01-1994
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer  Ryckebosch, A

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/07471

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark : Although claims 1-11 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**